Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium

Eligibility criteria

Inclusion Criteria:
* Age ≥ 60 and ≤ 90 years
* Diagnosis of normal cognition with at least one criterion for vascular risk*, subjective cognitive decline (preliminary diagnosis based on self-report question or eCog-12), mild cognitive impairment, or mild dementia based on standard research criteria
* Fluent in English or Spanish
* No contraindications to MRI including CVR
* No confounding neurologic, psychiatric, or medical disease
  *Participants with normal cognition must meet at least one criterion (diabetes, OR hypertension plus, OR MRI factors) for vascular risk prior to enrollment:
* Diabetes (at least one of the following):
  * Fasting (8-hour fast, usually overnight) blood sugar ≥126 mg/dL (≥7 mmol/L, or ≥1260 mg/L)
  * Random or Post-prandial blood sugar ≥200 mg/dL (≥11.11 mmol/L, or ≥2000 mg/L)
  * HbA1C ≥6.5% (or ≥47.5412 mmol/mol)
  * Treatment with an anti-diabetic medicine
* Hypertension plus (at least two of the following):
  * Use of anti-hypertensive medications for lowering blood pressure for ≥ 10 years
  * Current use of two or more anti-hypertensive medications for lowering blood pressure
  * One measured blood pressure in a research or clinical setting in the last 2 years with SBP ≥140 or DBP ≥90
  * A second measured blood pressure in a research or clinical setting on a different date in the last 2 years with SBP ≥140 or DBP ≥90
  * Evidence of likely HTN end-organ damage (e.g., LVH, albuminuria, eGFR\<60, CHF)
* MRI factors (at least one of the following):
  * Peri-Ventricular Fazekas Extent Grade or Deep Fazekas Extent Grade ≥ 2
  * 1 or more microbleeds
  * 1 or more lacunar infarcts
Exclusion Criteria:
* Neurologic Disease: Based on the available data and investigator's impression, exclude those with confounding neurologic disease that would interfere with test performance or with biomarker analysis:
  * Frontotemporal lobar degeneration (FTLD)
  * Lewy body dementia (LBD)
  * Parkinson's disease
  * Multi system atrophy
  * Traumatic brain injury (TBI)-related cognitive impairment
  * TBI that interferes with MRI biomarker analyses (e.g., large volume traumatic lesion)
  * Non-small vessel strokes that interfere with test performance (e.g., post-stroke cognitive impairment or aphasia)
  * Non-small vessel strokes that interfere with MRI biomarker analysis (e.g., large volume strokes)
  * CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy)
  * Individuals known to be receiving, or planning to receive, anti-amyloid immunotherapy*
  * Other neurologic conditions that interfere with test performance or biomarker analysis
    * Individuals prescribed anti-amyloid immunotherapy after MarkVCID enrollment should be kept in the study.
* Medical and Psychiatric Conditions: Exclude those with medical and psychiatric conditions that would confound the course or interfere with test performance:
  * Schizophrenia or other active/severe psychotic disorders
  * Medical or psychiatric conditions likely to interfere with participation or retention (e.g., metastatic or malignant CNS cancer, active/severe depression or anxiety, HIV- Associated Neurocognitive Disorder)
  * Contraindications to MRI procedures, such as:
    * Claustrophobia
    * Cardiac pacemaker
    * Intracranial clips/metal implants
  * Contraindications to CVR:
    * COPD or other respiratory condition requiring oxygen therapy
    * Asthma or other respiratory condition requiring current use of medications such as inhalers

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2025-01-29